Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Retin-A Micro 0.04% facial acne treatment · 1 trial · 1 indication
Change from Baseline to Week 12 (Week 12 minus Baseline) in the total non-inflammatory acne lesion count. Facial acne lesion counts consisted of non-inflammatory lesions and inflammatory lesions. The total non-inflammatory acne lesion count is the sum of open and closed comedones, change from Baseline was calculated as the value after Baseline minus the baseline value, and negative changes indicated lesion improvement.
| Arm | Type | Description |
|---|---|---|
| Retin-A Micro | EXPERIMENTAL | Retin-A Micro 0.04% facial acne treatment used once daily |
| Vehicle Control | PLACEBO_COMPARATOR | Color matched facial gel vehicle control used once daily |
| Name | Type | Description |
|---|---|---|
| Retin-A Micro 0.04% facial acne treatment | DRUG | Retin-A Micro 0.04% facial acne treatment used once daily |
| Vehicle control | DRUG | Color-matched facial gel vehicle control used once daily |
Inclusion Criteria: * Males and non-pregnant, non-nursing females, 9 to 11 years, with facial pediatric acne vulgaris * Minimum of 20 non-inflammatory lesions (open and closed comedones) * Minimum of 30 total facial lesions (sum of inflammatory and non-inflammatory) * Must have at least a rating of...
Retin-A Micro 0.04% is a small molecule facial acne treatment being studied for acne vulgaris. It is a topical formulation developed by Bausch Health Companies Inc. (BHC). The drug is currently in Phase 2 clinical development and is not yet approved by the FDA.
Retin-A Micro 0.04% is a retinoid, which works by affecting skin cell turnover and reducing inflammation. It is designed to treat acne vulgaris by unclogging pores and promoting the shedding of dead skin cells. The specific molecular target is not disclosed in the available information.
Retin-A Micro 0.04% is developed by Bausch Health Companies Inc., a pharmaceutical company traded under the ticker BHC. The company is conducting clinical trials for this acne treatment in the dermatology therapeutic area.
Retin-A Micro 0.04% is in Phase 2 clinical development. It is an investigational drug for acne vulgaris and has not received FDA approval. The drug is being studied in a completed Phase 2 trial with 110 participants.
Retin-A Micro 0.04% has one completed Phase 2 trial, NCT00907335, titled 'A Study of Acne Treatment in Children Ages 9 to 11'. This randomized, double-blind, placebo-controlled study enrolled 110 participants with acne vulgaris in the United States.
Retin-A Micro 0.04% is a brand name for a formulation of tretinoin, a retinoid used for acne. It is developed by Bausch Health Companies Inc. and is currently in Phase 2 trials for acne vulgaris in children aged 9 to 11.